12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Company News  |  Deals

Baxter, Onconova Therapeutics deal

Onconova granted Baxter exclusive rights to commercialize rigosertib in Europe. Onconova will receive $50 million up front and is eligible for up to $515 million in development and regulatory milestones, plus royalties and sales milestones. Rigosertib is in Phase III testing for...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >